Interview: Manni Kantipudi – CEO, GVK BIO, India
Manni Kantipudi, CEO of GVK BIO, talks about the evolution of the company, which he took from USD 20 million to its current USD 120 million, its future, its strategic…
Address: First Floor, Su Motor Complex,, Veena Nagar, Mulund West, Mumbai-400 080,India
Tel: 022 30781000
Web: http://truecare.in/Truecare/
Abbott is a diverse global health care company with scientific expertise and products that address the varied healthcare needs of the people.
Abbott has been present in India for over 100 years now starting operations in 1910. The company’s pharmaceutical offerings expanded significantly over the years through organic growth and acquisitions. Currently Abbott is India’s largest pharmaceutical company in 2010 with the acquisition of Knoll, Solvay pharmaceuticals and Piramal Healthcare (domestic formulations division)
The product portfolio in India can be categorized into three broad categories – Pharmaceuticals, Nutrition and Medical devices.
Abbott serves the evolving healthcare needs of Indian consumers by introducing products backed by strong R&D. In addition our Established Pharmaceuticals Division (EPD) offers an expanding portfolio of branded generic drugs.
Our global citizenship priorities address the principal economic, social and environmental challenges necessary for a healthy society and a favorable business environment.
With over 13,000 people, India is Abbott’s largest employee base outside the United States. The company seeks to attract, retain and develop the best talent to ensure a healthy, safe, fulfilling work environment for all employees in India.
The product portfolio in India can be categorized into three broad categories – Pharmaceuticals, Nutrition and Medical devices.
Abbott serves the evolving healthcare needs of Indian consumers by introducing products backed by strong R&D. In addition our Established Pharmaceuticals Division (EPD) offers an expanding portfolio of branded generic drugs.
Our global citizenship priorities address the principal economic, social and environmental challenges necessary for a healthy society and a favorable business environment.
Manni Kantipudi, CEO of GVK BIO, talks about the evolution of the company, which he took from USD 20 million to its current USD 120 million, its future, its strategic…
R.S. Subramanian, country manager and Sandeep Juneja, vice president – Sales and Marketing, DHL Express India, explain why the world’s leading express logistics company is a trusted and accountable service…
A passionate advocate for Indian patients, Sanjiv Navangul, managing director of Janssen India, discusses the company’s public health work in the field of tuberculosis (TB) and multi-drug resistant TB (MDR-TB)…
A strong advocate for quality, Dilip Surana, chairman and managing director of Micro Labs, explains how the company’s strong focus on the quality of its products and move to specialty…
Amit Mookim, IQVIA’s general manager for South Asia, discusses the major trends impacting the Indian pharmaceutical market and how Indian companies are rethinking their commercial strategies and becoming more specialized…
Satish Kumar Singh (managing director) & Shashi Shekhar Kumar (vice president International Business) from M/s Cachet Pharmaceuticals Pvt. Ltd., discuss their success with special reference to marketing, distribution and operating…
A pioneer of the biotechnology industry in India and the head of the country’s leading biotechnology enterprise, Kiran Mazumdar-Shaw, discusses the recent US FDA approval of Ogivri™, the first biosimilar…
A nationwide renowned neonatologist and member of the High Level Expert Group on Universal Health Coverage, NITI Aayog’s medical expert, Dr. Vinod K. Paul introduces the work that the government…
Newly appointed commissioner of the Food & Drugs Administration (FDA) of the Indian state of Maharashtra, Dr. Pallavi Darade, shares her objectives to further consolidate the FDA’s positioning as a…
With the Indian public healthcare apparatus straining at the seams to provide affordable access to treatments to the country’s vast population, two pioneering pharmaceutical multinationals – Novartis and Janssen –…
Kanchana TK, director general of the Organisation of Pharmaceutical Producers of India (OPPI), the association which represents the interests of research-based pharmaceutical companies in India, discusses regulatory reform and how…
Janmejay Vyas, chairman of the Dishman Group, shares the story of his success in establishing a trustworthy relationship with the strictest drug regulator in the world, the US FDA. Mr…
See our Cookie Privacy Policy Here
